This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

IASLC LALCA, Mexico City, Mexico,1 7-19 October 2019

Second-line afatinib vs erlotinib for advanced lung squamous cell carcinoma: final analysis of the Phase 3 LUX-Lung 8 trial

Glenwood D Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Jian Hong, Yu Yongfeng, Shaun Bender, Agnieszka Cseh, Enriqueta Felip

lalca_ll8_poster_.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

FOR HEALTHCARE PROFESSIONALS ONLY.

links_to_3rd_party.jpg